New strategy for safer CAR T cell therapy in lymphomas
In the treatment of aggressive lymphomas and blood cancer (leukaemia), so-called chimeric antigen receptor T cells (CAR T cells) are increasingly being used. For this therapy, immune cells are taken from patients and programmed by means of genetic engineering to detect proteins on the malignant tumour cells. Back in the body, the CAR T cells then fight the cancer cells. Due to some heavy side effects, this therapy requires extreme caution and long hospital stays. Scientists at University Hospital Cologne are therefore researching ...










